Paul J. Norman, PhD - Diversity of KIR & HLA and their interaction in human populationVideo: Part of ASHI 2021 Virtual User Group Meeting
Paul J. Norman, PhD
University of Colorado, Denver - Anschutz Medical Campus (https://medschool.cuanschutz.edu/biomedical-informatics-and-personalized-medicine/labs/norman-lab/people)
For Further Information Visit: https://www.omixon.com/
Dr. Karen Sherwood -Clinical Implementation of Omixon's NanoTYPE AssayVideo: Part of ASHI 2021 Virtual User Group Meeting
Dr. Karen Sherwood
Director of Clinical Immune Research, Vancouver General Hospital, Vancouver, BC
For Further Information Visit: https://www.omixon.com/
HLA Twin™ 4.1 Software TutorialIn this video we will outline the new features of our latest release, HLA Twin™ 4.1.
Webinar – ABO Typing Using Molecular TechniquesWelcome to our latest Omixon Academy Webinar about ABO genotyping using molecular methods in the field of transfusion medicine.
- Dr. Martin Písačka (Head of Transfusion Dept., IHBT, Prague)
- Libor Kolesár (Senior Field Application Scientist, Omixon)
- Efi Melista (Head of Product, Omixon)
- ABO typing using molecular techniques: importance and applications
- What is new in HLA Twin?
- Closing remarks and announcements
- Live Q & A
Agenda do Webinar:
- Bem-vindo por Ellia Gomes e Renata Santos
- Apresentação do Holotype HLA - Ellia Gomes
- Apresentação do Software Twin - Renata Santos
- Sessão de Perguntas e Respostas ao Vivo
The Human Leukocyte Antigen - Basic Immunological RolesLearn more about the role of the human leukocyte antigen (HLA) system in and beyond transplantation!
Please find the first part of our HLA Educative Series that targets a wide range of knowledge levels. We start with their basic immunology that will be followed by their roles in transplantation, and the genetics of HLA. As to the latter we will also cover how next-generation sequencing (NGS) is delivering accuracy and efficiency to HLA typing!
Omixon HLA Explore - New Genotyping Software for HLA by NGSWelcome to HLA Explore, Omixon`s NGS-based HLA Typing software for researchers in genetics/genomics. It is flexible and customizable to handle all sequencing data types from short Illumina and Ion Torrent reads to long read technologies generated by PacBio or Oxford Nanopore.
HLA Explore can analyze data from any experiment type such as targeted exons, targeted whole genes, whole MHC, whole exome or whole genome. It is a high-performance, high-throughput and high-resolution multi-sample software for genotyping analysis, interpretation and reporting.
HLA Twin™ - The World’s Most Accurate HLA Genotyping SoftwareWelcome to HLA TWIN - the world’s most accurate HLA genotyping software from Omixon - the world leader in NGS-based HLA genotyping.
Building on three years of continuous innovation, HLA Twin was co-developed with the Holotype HLA NGS assay, licenced from the Children's Hospital of Philadelphia. Omixon is committed to developing the most advanced molecular diagnostics solutions with the highest quality products to meet every aspect of our customers’ needs.
Webinar - Changes on AFND to Support NGS in H&IEnjoy this presentation by Dr. Peter Meintjes (CCO, Omixon), Marcello Scala (Director of Sales, EMEA, Omixon) and our special guest speaker, Prof. Derek Middleton PhD, DSc, Lab Director of Royal Liverpool and Broadgreen University Hospital about "Changes on Allele Frequencies Net Database to Support NGS in Histocompatibility and Immunogenetics". The webinar was held on the 10th of March 2016.
- Introduction of Omixon
- Introduction of Derek Middleton
- Presentation by Derek Middleton
- HLA Twin Software 1.1.3 Presentation, Live Demo
- Q&A Session
Omixon at ASHI 2015The ASHI event went smashingly for Omixon yet again, with a full soccer-sized team of 11 making the trip from all corners of the US and across the pond from Europe.
Omixon hosted four software training workshops on the Monday – the advanced workshops were particularly popular and the FAS team received excellent reviews from the attendees.
Tuesday saw the Lunchtime Symposium where Omixon had four guest presenters and CEO Tim Hague and CCO Peter Meintjes announced the results of the Holotype HLA Early Access Program.
For more, visit our website: omixon.com
Webinar - The Holotype HLA™ Typing SystemAre you Interested in the Specific Challenges and Optimization of NGS for HLA?
Enjoy this presentation by Tim Hague (CEO, Omixon), Craig Funnell (Director, Sales & Marketing, Omixon) and our very special guest, Prof. Dimitri Monos from The Children's Hospital of Philadelphia on The Holotype HLA™ Typing System - Optimizing NGS to Address the HLA Typing Challenge, which was held on the 30th of June 2015.
- Introduction & Benefits of NGS
- Our Experience with the Holotype HLA Assay Development
- Specific Challenges of NGS
- HLA Twin Software Overview, Live Demo
- Advanced Features for Software Optimization, within Demo
- Summary & Benefits
- Q&A Session
Omixon Academy Webinar Holotype HLA 2014-09-18Are you interested in Next Generation HLA Typing?
Enjoy this presentation by Dr. Peter Meintjes on Holotype HLA™ - HLA Genotyping Assay and Software for NGS data.
- The Relevance and Challenges of HLA Genotyping
- Next Generation Sequencing Overview
- Introducing... Holotype HLA™
- Omixon HLA Twin Demo
- Summary & Benefits, Q&A
Peter Meintjes, PhD
Peter has a passion for driving commercial success through disruptive innovations in biotechnology and medicine and is currently the Director of US Operations at Omixon. He is responsible for all aspects of manufacturing Holotype HLA and the sales process from business development through account management and post-sales support. Peter has over five years experience in international Business Development, Sales and Marketing of software products for Genomics and Molecular Biology and has a technical background, with a PhD in microbial genomics from the University of Auckland and is an expert in DNA Sequencing, Microbiology, Genetics/Genomics, Evolution and Bioinformatics Software.
T-Cell Receptor with HLA-A and Bound PeptideThe main role of Class-I HLA molecules is to present peptides on the cell surface to T-cell receptors (TCRs).
When a TCR interacts with a HLA protein (HLA-A*24 in the video), both the HLA-A amino acids (AAs), and other aminoacids from the
presented peptide make direct contacts to the TCR.
The presented peptides are usually small (8-10 AA long) fragments derived from proteins of the cell. These proteins are the "normal" ones building up the cells, and the presented small peptides everywhere on the the surface of each of our cells.
Once a pathogen (bacterium/virus) manages to enter to the cell, its peptides will also be presented on the cell surface. These peptides are expected to be different from the host's peptides (as proteins building up viruses and bacteria are different) the pattern on the surface of the HLA protein will be also different - this is what the T-cell receptor will recognize as "foreign".
On this animation the 3VXR crystal structure shows that principal interactions in the HLA-peptide-TCR complex. You can see that the peptide (a piece from the HIV virus) is not completelly buried in the HLA-A protein, there are amino acids dangling into the intercellular space, and these can make direct interactions (H-bonds, pi-pi stackings, van der Waals) with the corresponding amino acids of the T-cell receptor. There are important water molecules as well, these are not visualized to make the picture less cluttered.
These interactions are governed by the density of electrons around different atom types. The electrostatic potential around this ramified structure can be estimated using Poisson-Boltzmann electrostatics, and visualized by PyMOL. Amino acids building up proteins are generally polar molecules (though many has apolar sidechains), therefore when calculating electrostatic potentials, one have to consider the polar water molecules solvating the protein. Electrostatic potential differences in the binding region depict those patterns that are responsible for the binding of the HLA and TCR molecules. Most of the surface shown is gray (water is surrounding the proteins) the colourful patterns in and around the binding cleft are what a T-cell receptor can recognize as an epitopes.
Animation by pymol (www.pymol.org)
Electrostatics by APBS (www.poissonboltzmann.org)
Created by Szilveszter Juhos, Senior Scientist, Omixon.
For more information, contact email@example.com
Visit the Omixon Academy website: http://www.omixon.com/omixon-academy-home/
Registry Match - High ThroughputSpecial thanks to Dr. Marco Shaefer, Dr. Wolfgang Peter and their very skilled laboratory team, we very much enjoyed the experience working with you on the Holotype HLA training.
The Omixon Team
EFI 2015 - Success for AllApril 2015, Omixon had a tremendous experience in the amazingly picturesque city of Geneva Switzerland – the backdrop for EFI 2015, facilitated by Prof. Jean-Marie Tiercy and Dr. Jean Villard and their team of professional event managers.
Our booth was buzzing continuously with technical repartee and multiple software demos, and many participants were very interested in our NGS genotyping solutions for HLA. To further demonstrate Holotype HLA’s performance, Omixon held a series of three 1-hour workshops on Sunday April 26, for several HLA field experts to practice using our HLA Twin software hand-on in a class-room-environment, pampered by our support colleagues, Efi Melista (Field Application Scientist) and Agnes Pasztor (Customer Support Manager).
The activity in our booth and workshops was complemented by the Omixon Symposium on Monday April 27, attended by over 100 professionals from the HLA community. Introductory presentations from Marcello Scala (Sales Manager, EMEA & Asia) and Tim Hague (CEO) were followed by personal reports from some of our evaluators, presented by guest speakers Lydie Brunet (Geneva University Hospital), Mette Christiansen (Aarhus University Hospital, Denmark) and Amalia Dinou (Biomedical Foundation of Academy of Athens, Greece) – thank you again to our special guests for talking at our event!
The fun did not stop there – Omixon continued to entertain attendees with a number of side-shows, such as our wine-tasting event (“Cheers”), scientific posters sessions (3 posters), and a comic-posters lucky draw (winners to be announced soon).
Thank you again to the EFI 2015 organisers, we certainly look forward to seeing you in Kos, Greece for 2016.
Visit our blog on www.omixon.com/blog to read more, and contact firstname.lastname@example.org for the presentation we gave at our Symposium.
Holotype Goes Global - Genotyping the Planet'Holotype Goes Global' - a preview of some destinations we visited during the Early Access Program (EAP) for Holotype HLA - with over 1,500 samples tested by 25 participant laboratories, in more than 13 countries across the globe.
The EAP for Holotype HLA will officially be closed at EFI 2015, following which the combined Assay + Software HLA genotyping product will be fully ready for commercialisation.
Join us at EFI in Geneva, Switzerland, April 26th to 30th, 2015...Omixon will have various activities going on:
- Booth #4
- Posters (3 x)
- HLA Twin, Workshops (Sun, 26 April, 11am to 1pm)
- Holotype HLA, Symposium (Mon, 27 April, 11:30 pm)
For more information, contact email@example.com, or visit the Holotype HLA product page on Omixon's website: http://www.omixon.com/holotype-hla/
Omixon Academy Webinar - Rare and Null Allele Detection with Omixon HLA Twin™Online presentation by Tim Hague, Craig Funnell and Agnes Pasztor, with a comprehensive introduction to Omixon’s Holotype HLA Genotyping assay and HLA Twin™ Genotyping software.
The presentation includes examples of HLA Twin's quality metrics and the dual algorithm, and a live demo on how to handle rare and null allele detection.
Visit the Omixon Academy website for more webinars, workshops and useful educational material: http://www.omixon.com/omixon-academy-home/
Omixon at ASHI 2014Omixon attended ASHI (The American Society for Histocompatibility & Immunogenetics) in Denver, USA, October 20 to October 25, 2014. The event was extremely successful, with both the HLA Twin ‘Novel Allele Discovery’ Workshops and the Holotype HLA Luncheon oversubscribed, with the Omixon booth occupied with interested attendees all day. Omixon was also featured in five posters and three scientific talks from prominent speakers.
The Luncheon event saw the launch of Omixon’s new Holotype HLA combined assay and software product, including three guest speakers from Early Access Program labs – Laurine Bow from Yale, Julio Delgado from ARUP and Medhat Askar from Cleveland Clinic – plus speeches from Dimitri Monos (from The Children’s Hospital of Philadelphia) and Peter Meintjes and Tim Hague (both Omixon).
Visit our blog on www.omixon.com to read more...
HLA QuestHolotype HLA protocol training with Omixon's Field Application Scientist (FAS), at Dr. Ryad Tamouza's HLA laboratory at St. Louis Hospital, in Paris.
Special thanks to Dr. Tamouza and his talented laboratory team, we very much enjoyed the experience working with you.
In memory of Prof. Jean Dausset, Noble prized scientist, and discoverer of HLA.
The Omixon Team
Omixon at ESHG 2013 coferenceOur CEO, Attila Berces is saying a few words about ESHG conference that was a great succes for Omixon.